Piper Jaffray Starts Celyad SA (CYAD) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UPDATE: UBS Starts Celyad SA (CYAD) at Buy
July 14, 2015 8:22 AM EDT(Updated - July 14, 2015 8:43 AM EDT)
UBS initiates coverage on Celyad SA (NASDAQ: CYAD) with a Buy rating and a price target of $82.00.
Analyst Andrew Peters commented, "We are initiating coverage on Celyad SA with a Buy rating and $82 price target following an extensive analysis of the phase-3 C-Cure program in heart failure as well as the NK-based CAR-T technology currently in phase-1 trials. We believe initial proofof-concept data from... More
